RG 2133
Alternative Names: RG2133; Triacetyluridine - Repligen; Uridine prodrugLatest Information Update: 20 Feb 2007
Price :
$50 *
At a glance
- Originator Repligen
- Developer Repligen Corporation
- Class Antidepressants; Chemoprotectants; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Metabolic disorders; Mood disorders; Parkinson's disease
Most Recent Events
- 20 Feb 2007 Discontinued - Phase-I/II for Affective disorders in USA (PO)
- 20 Feb 2007 Discontinued - Preclinical for Parkinson's disease in USA (PO)
- 22 Nov 2004 Preclinical trials in Parkinson's disease in USA (PO)